No Data
No Data
NeuroSense Highlights PARADIGM Clinical Trial Data; Co To Submit 12-Month Data To FDA To Discuss Path Forward
In the study, complication-free survival revealed a 57% difference in favor of PrimeC over placebo after 12 months of treatment in the Intent to Treat (ITT) population and demonstrated an outcome of 7
Express News | Neurosense Therapeutics Ltd - Intends to Submit Results to Regulatory Agencies, Including FDA, to Discuss Primec's Path Forward in Short Term
Express News | Neurosense Therapeutics Ltd - Paradigm ALS Clinical Trial Demonstrates up to 73% Improved Complication-Free Survival
NeuroSense's PARADIGM ALS Clinical Trial Demonstrates Up to 73% Improved Complication-Free Survival Following Statistically Significant Slowing of Disease Progression
Buy Rating Affirmed on Neurosense Therapeutics Following Promising PrimeC Trial Results
This Cheap Biotech Offers Investors a Play on ALS If Trial Data Continues to Impress
By Ciara Linnane The fatal illness, also called Lou Gehrig disease, has few treatment options NeuroSense Therapeutics Ltd.'s stock rose 6.5% Tuesday, as analysts cheered data from the biotech's late
No Data